$AROC

Archrock, Inc. (AROC): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Archrock, Inc. (AROC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 tm2618970d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 June 17, 2026 Mohit Singh [***] Re: Employment Terms Dear Mr. Singh I am pleased to offer you the position of Senior Vice President and Chief Financial Officer of Archrock, Inc. (the "Company") on the terms and conditions

Original reporting
Published Jun 25, 2026, 9:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 25, 2026, 9:17 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$AROC
Neutral
medium confidence
Mentioned
$AROC
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AROCNeutralLow
01

Why it matters

The newest concrete item is the offer letter terms for Mohit Singh as CFO, including at-will employment, short-term incentive eligibility, sign-on equity, and severance/change-of-control agreements (details referenced via exhibits).

02

Market read

This is primarily governance/compensation news; it may cause a small sentiment adjustment around leadership continuity, but it does not provide new financial performance or guidance.

03

What to watch

If the new CFO’s severance/change-of-control structure is unusually protective or signals governance/turnover risk, it could matter for longer-horizon risk pricing—even though the excerpt doesn’t quantify it.

Relevance 6/10Novelty 5/10Timing: after-hours/filing update on executive appointment (filed 2026-06-25)

Background

The SEC filing is an 8-K Item 5.02 covering departures/elections/appointments and compensatory arrangements for certain officers.

Company-level read

Ticker impact

$AROCNeutralMedium confidence
Context

Archrock’s 8-K discloses the appointment of Mohit Singh as Senior Vice President and CFO, with sign-on equity and severance terms.

Expected impact

Likely limited near-term impact; any reaction should be modest unless paired with guidance, restatements, or strategic changes not included here.

Evidence & confidence

The filing is an executive-compensation/appointment disclosure (8-K Item 5.02) and does not include earnings, guidance, or material business changes; however, leadership changes can still affect sentiment at the margin.

Market effects

No direct sector read-across; this is company-specific executive/compensation documentation.

None indicated beyond Houston-based corporate operations.

None indicated.

Counterpoint

The market may treat this as routine CFO onboarding paperwork; without any stated financial targets or strategy changes, price impact may be negligible.

Key entities

  • Archrock, Inc.

    Subject of the SEC 8-K; disclosed CFO appointment and related compensatory arrangements.

  • Mohit Singh

    Named in the exhibit as the incoming Senior Vice President and Chief Financial Officer.

Related articles

$AROCMedAI 8/10

Archrock (AROC) Q2 2026 Earnings Call Transcript

Archrock (AROC) reported Q2 2026 adjusted EBITDA of $213 million and adjusted EPS of $0.38. Contract operations revenue rose to $329 million, with adjusted gross margin at 71% and horsepower utilization at 94.4%. Aftermarket services revenue fell to $42 million. Adjusted free cash flow was $67 million, with $39 million returned via dividends. Full-year 2026 adjusted EBITDA guidance was narrowed to $865 million to $885 million.

$AROCMedAI 8/10

Archrock Miss Q2 Earnings & Revenues Estimates on AMS Weakness

Archrock (AROC) reported Q2 2026 adjusted EPS of 38 cents, missing the Zacks Consensus by 17.4%, and revenue of $371.2 million, below the $390.4 million estimate. The shortfall was attributed to weaker aftermarket services (AMS) versus resilient contract operations. Archrock raised its dividend to 23 cents and tightened 2026 adjusted EBITDA guidance to $865-$885 million.

$AROCMed

Archrock, Inc. (AROC): Results of Operations and Financial Condition

Archrock, Inc. (AROC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ ​ Archrock Reports Second Quarter 2026 Results ​ HOUSTON, August 4, 2026 - Archrock, Inc. (NYSE: AROC) (“Archrock” or the “Company”) today reported results for the second quarter 2026. Second Quarter 2026 Highlights ● Revenue for the second quarter of 2026 was $3

MedAI 8/10

Piraeus Bank S.A.: Ethniki Insurance Priced Its Inaugural €200mn Tier 2 and Restricted Tier 1 Perpetual Bonds

Piraeus Bank's subsidiary, Ethniki Insurance, priced its first €200mn subordinated bond issuance, comprising €100mn Tier 2 bonds at 5.25% and €100mn RT1 perpetual bonds at 6.875%. The offering was 3.0x oversubscribed, with strong international investor demand. The bonds will list on the Luxembourg Stock Exchange. Ethniki Insurance's Solvency II ratio stands at 190% post-issuance, according to the company.

$NVSMedAI 8/10

Novartis halted eight clinical trials of its experimental cell therapy rap-cel after three patients died from severe immune reactions

Novartis halted eight clinical trials of its experimental cell therapy rap-cel after three patients died from severe immune reactions. The pause affects trials for autoimmune and neurological disorders. Novartis is reviewing the deaths and sharing information with health authorities. Bristol Myers also paused studies of its rival CAR T-cell treatment zola-cel. Novartis shares rose 4% on Tuesday.